申请人:Merck Sharp & Dohme, Ltd.
公开号:US06071928A1
公开(公告)日:2000-06-06
The present invention relates to compounds of formula (I), wherein R is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, which groups are optionally substituted by hydroxy, C.sub.1-4 alkoxy or NR.sup.a R.sup.b, where R.sup.a and R.sup.b each independently repesent hydrogen or C.sub.1-4 alkyl; or R is C.sub.1-4 alkyl substituted by Ar, and optionally further substituted by one or both of R.sup.4 and R.sup.5 ; R.sup.1, R.sup.2 and R.sup.3 represent a variety of substituents; R.sup.9 and R.sup.10 are each hydrogen, halogen, C.sub.1-6 alkyl, CH.sub.2 OR.sup.c, oxo, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b where R.sup.c represents hydrogen, C.sub.1-6 alkyl or phenyl; X is --CH.sub.2, or --CH.sub.2 CH.sub.2 --; Y is --CH--, --CH.sub.2 --, --CH.sub.2 CH-- or --CH.sub.2 CH.sub.2 --, with the proviso that the sum total of carbon atoms in X+Y is 2 or 3; and when Y is --CH-- or --CH.sub.2 CH--, the broken line is a double bond; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, anesis and postherpetic neuralgia. ##STR1##
本发明涉及式(I)的化合物,其中R为C.sub.1-6烷基,C.sub.2-6烯基,C.sub.2-6炔基,C.sub.3-7环烷基,C.sub.3-7环烷基C.sub.1-4烷基,这些基团可选地被羟基,C.sub.1-4烷氧基或NR.sup.aR.sup.b取代,其中R.sup.a和R.sup.b各自独立地表示氢或C.sub.1-4烷基;或R为被Ar取代的C.sub.1-4烷基,并可选地进一步被R.sup.4和R.sup.5中的一个或两个取代;R.sup.1,R.sup.2和R.sup.3表示各种取代基;R.sup.9和R.sup.10分别为氢,卤素,C.sub.1-6烷基,CH.sub.2OR.sup.c,氧代,CO.sub.2R.sup.a或CONR.sup.aR.sup.b,其中R.sup.c表示氢,C.sub.1-6烷基或苯基;X为--CH.sub.2或--CH.sub.2CH.sub.2--;Y为--CH--,--CH.sub.2--,--CH.sub.2CH--或--CH.sub.2CH.sub.2--,但要求X+Y中碳原子的总数为2或3;当Y为--CH--或--CH.sub.2CH--时,断裂线为双键;或其药学上可接受的盐。这些化合物在疼痛、炎症、偏头痛、麻醉和带状疱疹后神经痛的治疗或预防中特别有用。##STR1##